Online English Summarizer tool, free and accurate!
In January, an expert advisory panel of the FDA debated whether florbetapir was
ready for marketing. The group did not suggest that the FDA approve the drug at
this time. Still, the experts said they made the judgment based on available
information. And they asked for more information. They also set conditions for
accepting florbetapir.
One condition is for the manufacturer to show evidence that florbetapir correctly
identifies plaques. The other condition is that the manufacturer prepare a training
program for experts in nuclear medicine. The advisory panel said the doctors reading
the test need additional education to correctly identify the plaques.
The Food and Drug Administration will decide next month whether to accept the
panel’s suggestions. The FDA normally follows the advice of its expert advisers, but
not always.
If it is approved, florbetapir would be the first agent permitted to measure plaque
deposits in living patients. Still, the presence of plaques does not prove that a patient
has Alzheimer’s disease. Doctors say some people with amyloid plaques in their
brains do not have the condition.
An estimated thirty million people around the world have Alzheimer’s disease. In
the United States alone, more than five million people suffer from this presently
incurable brain disorder.
Alzheimer’s affects memory and personality -- those qualities that make a person an
individual. At first, people with the condition forget simple things, like where they
left the keys to their car. But as time passes, they forget more and more. They may
forget what a key is used for.
Patients forget the names of their husbands, wives or children. Then they forget who
they are.
Finally, they remember almost nothing. It is as if their brains die before the other
parts of the body. Victims of Alzheimer’s do die from its effects or conditions linked
to it. But death may not come for many years.
Dementia is the loss of thinking ability that is severe enough to interfere with daily
activities. It is not a disease itself. Instead, dementia is a group of signs of some
conditions and diseases.
In January, an expert advisory panel of the FDA debated whether florbetapir was
ready for marketing. The group did not suggest that the FDA approve the drug at
this time. Still, the experts said they made the judgment based on available
information. And they asked for more information. They also set conditions for
accepting florbetapir.
One condition is for the manufacturer to show evidence that florbetapir correctly
identifies plaques. The other condition is that the manufacturer prepare a training
program for experts in nuclear medicine. The advisory panel said the doctors reading
the test need additional education to correctly identify the plaques.
The Food and Drug Administration will decide next month whether to accept the
panel’s suggestions. The FDA normally follows the advice of its expert advisers, but
not always.
If it is approved, florbetapir would be the first agent permitted to measure plaque
deposits in living patients. Still, the presence of plaques does not prove that a patient
has Alzheimer’s disease. Doctors say some people with amyloid plaques in their
brains do not have the condition.
An estimated thirty million people around the world have Alzheimer’s disease. In
the United States alone, more than five million people suffer from this presently
incurable brain disorder.
Alzheimer’s affects memory and personality -- those qualities that make a person an
individual. At first, people with the condition forget simple things, like where they
left the keys to their car. But as time passes, they forget more and more. They may
forget what a key is used for.
Patients forget the names of their husbands, wives or children. Then they forget who
they are.
Finally, they remember almost nothing. It is as if their brains die before the other
parts of the body. Victims of Alzheimer’s do die from its effects or conditions linked
to it. But death may not come for many years.
Dementia is the loss of thinking ability that is severe enough to interfere with daily
activities. It is not a disease itself. Instead, dementia is a group of signs of some
conditions and diseases.
Summarize English and Arabic text using the statistical algorithm and sorting sentences based on its importance
You can download the summary result with one of any available formats such as PDF,DOCX and TXT
ٌYou can share the summary link easily, we keep the summary on the website for future reference,except for private summaries.
We are working on adding new features to make summarization more easy and accurate
يهدف إلى دراسة الأديان كظاهرة اجتماعية وثقافية وتاريخية، دون الانحياز إلى أي دين أو تبني وجهة نظر مع...
تعريف الرعاية التلطيفية وفقا للمجلس الوطني للصحة والرفاهية ، يتم تعريف الرعاية التلطيفية على النح...
Risky Settings Risky settings found in the Kiteworks Admin Console are identified by this alert symb...
الممهلات في التشريع الجزائري: بين التنظيم القانوني وفوضى الواقع يخضع وضع الممهلات (مخففات السرعة) عل...
Lakhasly. (2024). وتكمن أهمية جودة الخدمة بالنسبة للمؤسسات التي تهدف إلى تحقيق النجاح والاستقرار. Re...
Management Team: A workshop supervisor, knowledgeable carpenters, finishers, an administrative ass...
تسجيل مدخلات الزراعة العضوية (اسمدة عضوية ومخصبات حيوية ومبيدات عضوية (حشرية-امراض-حشائش) ومبيدات حي...
My overall experience was good, but I felt like they discharged me too quickly. One night wasn't eno...
- لموافقة المستنيرة*: سيتم الحصول على موافقة مستنيرة من جميع المشاركين قبل بدء البحث. - *السرية*: سي...
تعزيز الصورة الإيجابية للمملكة العربية السعودية بوصفها نموذجًا عالميًا في ترسيخ القيم الإنسانية ونشر...
وصف الرئيس الأمريكي دونالد ترامب، مساء الثلاثاء، الأوضاع الإنسانية في قطاع غزة بأنها "مأساوية"، متعه...
Mears (2014) A system of justice that could both punish and rehabilitate juvenile criminals was the ...